{"totalResults":376,"results":[{"description":"A summary of results from a phase III trial that compared the combination of pomalidomide (PomalystÂ®) and low-dose dexamethasone versus high-dose dexamethasone alone in patients with multiple myeloma that has progressed despite other treatments.","title":"Pomalidomide for Multiple Myeloma - National Cancer Institute","contentType":"cgvArticle","url":"https://www.cancer.gov/types/myeloma/research/pomalidomide-dexamethasone"},{"description":"This page lists cancer drugs approved by the Food and Drug Administration (FDA) for multiple myeloma and other plasma cell neoplasms. The list includes generic names, brand names, and common drug combinations, which are shown in capital letters. The drug names link to NCI's Cancer Drug Information summaries.","title":"Drugs Approved for Multiple Myeloma - National Cancer Institute","contentType":"cgvArticle","url":"https://www.cancer.gov/about-cancer/treatment/drugs/multiple-myeloma"},{"description":"NCI supports clinical trials studying new and more effective ways to detect and treat cancer. Find treatment clinical trials for multiple myeloma.","title":"Treatment Clinical Trials for Multiple Myeloma - National Cancer Institute","contentType":"nciAppModulePage","url":"https://www.cancer.gov/about-cancer/treatment/clinical-trials/disease/multiple-myeloma/treatment"},{"description":"A Cancer Currents blog post about research showing that individual tumor cells in patients with multiple myeloma may provide important clues about the genetic drivers of their disease.","title":"Circulating Multiple Myeloma Tumor Cells - National Cancer Institute","contentType":"cgvBlogPost","url":"https://www.cancer.gov/news-events/cancer-currents-blog/2016/myeloma-ctcs-genomic"},{"description":"The results of standard tests indicated that Valerie Winston was at risk for multiple myeloma. Read how an NCI combination therapy clinical trial helped her avoid the full impact of multiple myeloma.","title":"Stopping Multiple Myeloma with New Treatments - National Cancer Institute","contentType":"cgvArticle","url":"https://www.cancer.gov/research/infrastructure/clinical-trials/valerie-winston-clinical-trial-multiple-myeloma"},{"description":"A Cancer Currents blog on the approval of lenalidomide as maintenance therapy for patients with multiple myeloma who have received an autologous stem cell transplant.","title":"New Use for Lenalidomide in Multiple Myeloma - National Cancer Institute","contentType":"cgvBlogPost","url":"https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-lenalidomide-myeloma-maintenance"},{"description":"A Cancer Currents blog on a clinical trial showing that the combination of bortezomib, lenalidomide, and dexamethasone improves survival in multiple myeloma.","title":"Three-Drug Combination for Multiple Myeloma - National Cancer Institute","contentType":"cgvBlogPost","url":"https://www.cancer.gov/news-events/cancer-currents-blog/2017/three-drug-combination-myeloma"},{"description":"Plasma cell neoplasms occur when abnormal plasma cells form cancerous tumors. When there is only one tumor, the disease is called a plasmacytoma. When there are multiple tumors, it is called multiple myeloma. Start here to find information on plasma cell neoplasms treatment, research, and statistics.","title":"Plasma Cell Neoplasms (Including Multiple Myeloma)\u2014Patient Version - National Cancer Institute","contentType":"cgvCancerTypeHome","url":"https://www.cancer.gov/types/myeloma"},{"description":"As part of National Minority Cancer Awareness Week, we discuss multiple myeloma, a cancer that disproportionately affect minorities, and awareness of this cancer in African American communities.","title":"Multiple Myeloma Awareness and African American Disparities - National Cancer Institute","contentType":"cgvBlogPost","url":"https://www.cancer.gov/about-nci/organization/crchd/blog/2017/multiple-myeloma-disparities"},{"description":"There are several types of plasma cell neoplasms, including monoclonal gammopathy of undetermined significance (MGUS), isolated plasmacytoma of the bone, extramedullary plasmacytoma, and multiple myeloma. Find evidence-based information on plasma cell neoplasms treatment, research, and statistics.","title":"Plasma Cell Neoplasms (Including Multiple Myeloma)\u2014Health Professional Version - National Cancer Institute","contentType":"cgvCancerTypeHome","url":"https://www.cancer.gov/types/myeloma/hp"}]}